Document:

Amendment dated as of May 19, 2006 among Signet Laboratores, Inc.

 Exhibit 10.108 
 AMENDMENT 
 This Amendment (this “Amendment”), dated as of May 19, 2006 (the
“Effective Date”), is entered into by and among, Signet Laboratories, Inc., a Delaware corporation (“Signet”), Senetek Plc, a United Kingdom company (“Senetek”), Research Foundation for Mental Hygiene, Inc.
(“RFMH”) and Covance Antibody Services, Inc., a California corporation (“Covance”). 
 Senetek and RFMH are parties to an
Agreement dated July 21, 1994, and subsequently amended (the “Basic Agreement”). Senetek and Signet are parties to an Agreement dated January 1, 2005, and subsequently amended (the “Secondary Agreement”) concerning the
subject matter of the Basic Agreement. Signet and Covance are parties to an Asset Purchase Agreement dated April 10, 2006 (the “APA”) in which Covance has agreed to acquire substantially all of the assets of Signet and to assume
certain liabilities of Signet related to the assets acquired, including Signet’s rights and obligations under the Secondary Agreement arising on and after the effective date of such assignment (the “Closing Date”). 
 In consideration of the mutual covenants and conditions set forth below, the adequacy of which is acknowledged, the parties agree as follows: 

1. Senetek consents to the assignment of the Secondary Agreement as described above, waives any breach or default under the Secondary Agreement
arising from or related to such assignment, and releases Signet from all liabilities and obligations under the Secondary Agreement occurring on or after the Closing Date. RFMH consents to the assignment of the Secondary Agreement as described above
and waives any breach or default under the Basic Agreement arising from or related to such assignment. Covance agrees to pay, perform and discharge all liabilities and obligations of Signet under the Secondary Agreement arising on or after the
Closing Date. 
 2. It shall be a condition of Senetek’s and RFMH’s consents to the assignment of the Secondary Agreement pursuant
to paragraph 1 and their agreements therein that Covance shall be responsible only for liabilities and obligations under the Secondary Agreement arising on and after the Closing Date, that on the Closing Date Signet shall deposit with Silicon Valley
Bank, as escrow agent (the “Escrow Agent”), by wire transfer, the sum of Fifty Thousand Dollars ($50,000.00) to be held by the Escrow Agent pursuant to the terms of the form of Escrow Agreement annexed hereto as Exhibit B as security for
the prompt payment, performance and discharge by Signet of any and all liabilities and obligations of Signet under the Secondary Agreement arising prior to the Closing Date. Escrow shall be cleared within 30 days after the Closing Date. 

3. RFMH and Senetek confirm that the definition of “Licensed Cell Lines” for purposes of the Basic Agreement, and Senetek and Signet confirm
that the definition of “Cell Lines” for purposes of the Secondary Agreement, includes all cell lines set forth in Exhibit A, and that the expiry for all cell lines set forth in Exhibit A is July 1 0,2011. 
 4. RFMH agrees that in the event Senetek elects to terminate the Basic Agreement pursuant to Section 9.1 of the Basic Agreement, or RFMH elects to
terminate the Basic 

  

 - 1 - 

 
Agreement pursuant to (i) Sections 9.8 of the Basic Agreement or (ii) Section 9.2 of the Basic Agreement provided that Signet shall not
have been primarily responsible for the breach giving rise to RFMH’s right of termination, (a) RFMH shall promptly notify Signet in writing, and (b) Signet may, in its sole discretion, agree to assume all rights and future obligations
of Senetek pursuant to the Basic Agreement, as of the effective date of such termination, by notifying RFMH in writing within forty five (45) days of its receipt of such notice from RFMH, thereby establishing a direct contractual relationship
between RFMH and Signet pursuant to the then existing terms and conditions of the RFMH Agreement. For clarity, Signet shall not be required to assume any liability or obligation of Senetek, including but not limited to the liabilities associated
with the breach of agreement giving rise to RFMH’s option to terminate under Section 9.2, that arose prior to the time the direct contractual relationship between RFMH and Signet commenced. On and after the Closing Date, all references in
this paragraph 4 and in paragraph 5 and 6 shall be deemed replaced with references to Covance. 
 5. Signet, Senetek and Covance further
agree that the following sentence shall be added to section 3.5 of the Secondary Agreement: 
 “Where a Cell Line Product is not sold on
independent arm’s length terms, but is used by Signet or an affiliate of Signet, Net Sales shall include the fair market value of such products. Fair market value shall be deemed to be the average selling price for such product during the prior
calendar quarter. 
 6. Signet, Senetek, and Covance further agree that section 3.4 of the Secondary Agreement shall be replaced as follows:

 “In the event that Signet’s aggregate Net Sales of Cell Line Products for any calendar year (“Yearly Net Sales”) are
less than $1,880,000 (“Minimum Sales”), Signet shall remit to Senetek, together with the payment due for the fourth calendar quarter of such year, an amount equal to: 
 33% of the shortfall, if any, of Minimum Sales from Yearly Net Sales, 
 Aggregate payments to Senetek related to Net Sales for any calendar year, shall not be less than $860,000. 
  

 - 2 - 

 Signet, Senetek, RFMH and Covance have caused this Agreement to be executed, effective as of the
Effective Date. 
  

									
	SIGNET LABORATORIES, INC.	 		 	SENETEK PLC
					
	By	 	/s/ Ronald J. Casciato, Ph. D.	 		 	By	 	/s/ William O’Kelly
	Name:	 	Ronald J. Casciato, Ph. D.	 		 	Name:	 	William O’Kelly
	Title:	 	CEO	 		 	Title:	 	CFO
	Date:	 	May 19, 2006	 		 	Date:	 	May 21, 2006

  

									
	RESEARCH FOUNDATION FOR HYGIENE, INC.	 		 	COVANCE ANTIBODY SERVICES INC.
					
	By	 	/s/ Robert E. Burke	 		 	By	 	/s/ Christian Fritze
	Name:	 	Robert E. Burke	 		 	Name:	 	Christian Fritze
	Title:	 	Managing Director	 		 	Title:	 	Asst. VP
	Date:	 	May 30, 2006	 		 	Date:	 	June 2, 2006

  

 - 3 - 

 EXHIBIT A 
 4G8 6ElO
3F4 lEll 2H4 4D6 4B12 7D9 
 4B4 5-25 3-39 l7C7 D8B7 4E2 D6ElO 
 E6D7 lOD12 5F3 4H6 5C7 6Dll 
  

 - 4 -Contract for Personal Services between Senetek PLC and Brian Clark

 Exhibit 10.109 
 CONTRACT FOR PERSONAL SERVICES 
  

			
	Between	    	 Senetek PLC
 831 Latour Court, Suite
A
 Napa, California 94558
 (“Company”)

		
	And	    	 Brian Clark
 (“Chief
Scientist”)

 Scope 
 Effective August 1, 2006, Brian Clark is appointed Chief Scientist of Senetek PLC reporting to the Chairman and Chief Executive Officer of the Company. 
 Responsibility 
 The Chief Scientist will work under the direction of the Chairman and CEO of the Company. Such
direction will be principally provided via a rolling three month schedule of activities and objectives, mutually agreed by the Chief Scientist and the Chairman and CEO on a monthly basis. 
 Required Time Commitment 
 Chief Scientist will commit 31 weeks
per year to Senetek business and give Senetek business first order of priority with respect to other business activities in which he may be engaged. 
 Other Business Activities 
 Chief Scientist may be engaged in business activities other than Senetek but such business activities
shall not be of a nature that is directly competitive with Senetek and will be subject to Senetek priority as discussed in the paragraph above. 
 Fee

 $9,000 per month, payable on the 15th day of the month. 
 Location and Travel 

Chief Scientist will be based in Aarhus, Denmark. Expenses for travel undertaken on Senetek business will be reimbursed provided it is agreed in advance with the
Chairman and CEO. 
 Other Expenses and Support 
 Non-travel expenses undertaken for Senetek business will be reimbursed subject to advance approval by the Chairman and CEO or the CFO of Senetek PLC. 

 Contract for Personal Services 
 Page 2 
 Administrative support will be provided by Senetek PLC – Napa. 
 Term and Termination 
 This contact will remain in force until
terminated by either party to the contract. Such termination is solely at the will of either party, subject to a three month notice period. 
  

			
		
	/s/ Senetek PLC	 	August 8, 2006
	Senetek PLC	 	Date
		
	/s/ Brian Clark	 	August 8, 2006
	Brian Clark	 	DateAgreeement on Cooperative Research and Development - Phloretamide

 Exhibit 10.110 
 AGREEMENT ON COOPERATIVE RESEARCH AND DEVELOPMENT 
 between 
 Institute of Bioorganic Chemistry, Polish Academy of Sciences 
 (hereinafter referred to as “RESEARCHERS”) 
 and 
 Senetek PLC 
 831 Latour Court, Suite A

 Napa, California 94558 USA 
 (hereinafter referred to as “SENETEK”) 
 WHEREAS the RESEARCHERS, are performing basic research on phloretamide (the
“Compounds”) and are willing to provide to SENETEK samples of the Compounds and their analogs and related information developed by the RESEARCHERS, including any covered by patents and/or patent applications owned by the RESEARCHERS, for
testing, possible further development by SENETEK, and ultimately possible licensing to and commercialization by SENETEK; and 
 WHEREAS SENETEK is a company
developing pharmaceutical and cosmeceutical products and, in connection with such business, has made certain inventions regarding cytokinins and cytokinin analogs and methods of using them for various indications related to ameliorating signs of
aging and anti-inflammatory indications which are covered by the SENETEK PATENTS, as hereinafter defined; and 
 WHEREAS SENETEK is interested in testing and
evaluating, in cooperation with the RESEARCHERS, the Compounds, including the Compounds in combination with active ingredients covered by the SENETEK PATENTS, as hereinafter defined, developed by the RESEARCHERS and in obtaining licenses covering
such of these compounds as it may select as hereinafter provided. 
 NOW THEREFORE in consideration of above-mentioned premises the parties agree as
follows: 
  

 Phloretamide 

 ARTICLE 1 - DEFINITIONS 
 AFFILIATES as used herein shall mean any legal entity which, at the EFFECTIVE DATE or during the validity of this Agreement: 
  

	 	•	 	 directly or indirectly controls SENETEK, 

  

	 	•	 	 is under the same direct or indirect control as SENETEK, or 

  

	 	•	 	 is directly controlled by SENETEK 

 A
legal entity is considered controlling another: 
  

	 	•	 	 when it directly or indirectly owns over 50% (fifty percent) of the capital of this legal entity or more than 50% (fifty percent) of the voting rights of its
shareholders or associates; or 

  

	 	•	 	 when it has the direct or indirect de facto, directly or indirectly, the power to decide within this legal entity how the affairs shall be conducted.

 AGREEMENT as used herein shall mean this agreement and any and all f\nnexes, appendices and other addenda to it as it may be varied from
time to time 
 COMPOUNDS as used herein means phloretamide and its analogs and derivatives, developed, in-licensed or otherwise acquired by the RESEARCHERS
that may be used for any application. TESTING as used herein means any testing to determine the most suitable COMPOUNDS for patenting and further development. 
 RESEARCHERS as used herein means the the Institute of Bioorganic Chemistry, Polish Academy of Sciences 
 PARTY as used herein means any of the
PARTIES to this AGREEMENT as the case may be, and all of them when used in plural. 
 NEW PATENT APPLICATIONS as used herein means patent applications of the
RESEARCHERS to be prepared and filed in the name of the RESEARCHERS with technical and financial support of SENETEK, including those the subject of which is medical and cosmetic skincare applications of COMPOUNDS, and any and all patents issued
thereon or having a priority date based thereon. 
 RESEARCHERS’ PATENTS as used herein means any currently owned patents and patent applications of
RESEARCHERS covering COMPOUNDS, other than NEW PATENT APPLICATIONS. 
 SENETEK PATENTS as used herein means SENETEK’s issued patents (U.S. Patents
5,371,089, 5,602,139, 5,614,407,5,021,422, 5,164,394, and 5,151,425 and the corresponding international and foreign patents) related to the use of cytokinins for anti-inflammatory indications and for medical skin care applications and/or cosmetic
skin care applications, and any patents hereafter issued which are entitled to the same priority date(s) as such issued patents. 
  

 Phloretamide 
 2 

 PRODUCT as used herein means any product which or the process of production of which falls within a VALID CLAIM of a
patent licensed to SENETEK pursuant to this AGREEMENT. 
 SUB-LICENSEES as used herein mean any third parties who may obtain a license from SENETEK to
develop and/or commercially exploit any COMPOUND covered by a patent licensed to SENETEK pursuant to this AGREEMENT. 
 FIRST COMMERCIAL SALE as used herein
means the first commercial sale of a PRODUCT to a third party made by either SENETEK or its AFFILIATES or SUBLICENSEES. 
 NET SALES as used herein means the
gross amount invoiced by SENETEK and its AFFILIATES to their customers or by SUB-LICENSEES and their AFFILIATES to their customers, including distributors and third parties, for sales of PRODUCTS, less any normal trade discounts and credit notes
issued in respect of returned PRODUCTS, any purchase, sales, import, or value added taxes, and charges in respect to carriage. Should SENETEK or a SUB-LICENSEE sell PRODUCTS to an AFFILIATE (or vice-versa) which thereafter sell them to an unrelated
third party, the sales between the AFFILIATE (or SENETEK or SUBLICENSEE) and the unrelated third party (and not the sales between SENETEK or SUBLICENSEE and its AFFILIATE) shall be considered NET SALES. 
 VALID CLAIM as used herein means any claim of an issued and unexpired patent or a claim of a pending patent application licensed to SENETEK pursuant to this AGREEMENT
which has not been held un-patentable, invalid or unenforceable by a court or other government agency of competent jurisdiction and has not been admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise;
provided, however, that if the holding of such court or agency is later reversed by a court or agency with overriding authority, the claim shall be reinstated as a VALID CLAIM after the date of such reversal. 
 EFFECTIVE DATE as used herein shall mean the date of the last signature of this AGREEMENT by the PARTIES. 
 All plurals may be read in the singular and vice versa. 
 The headings are inserted for convenience only and shall be
ignored in construing this AGREEMENT. 
 ARTICLE 2 - SCOPE OF THE AGREEMENT 
  

	2.1	Subject to the terms and conditions of this AGREEMENT, SENETEK shall from time to time, as provided in Article 3 below, obtain from the RESEARCHERS such of the COMPOUNDS as SENETEK
may designate. 

  

	2.2	During the term of this AGREEMENT SENETEK will screen and conduct TESTING of these COMPOUNDS. 

  

 Phloretamide 
 3 

	2.3	If SENETEK finds one or more of the TESTED COMPOUNDS of interest and wishes to exploit it or them commercially, SENETEK and the RESEARCHERS will negotiate and sign license
agreements, as defined in Article 3.5 hereof. 

  

	2.4	SENETEK will pay royalty related to the NET SALES of PRODUCTS to RESEARCHERS as set in the ANNEX 1—License Agreement Term Sheet, attached to this AGREEMENT.

 ARTICLE 3 - DUTIES OF THE PARTIES 
  

	3.1	Promptly after the EFFECTIVE DATE, and thereafter at least once every calendar year, the RESEARCHERS shall provide SENETEK with a complete listing and description of all COMPOUNDS
developed, in licensed or otherwise acquired by the RESEARCHERS, together with all chemical and biological information in their possession with respect to such COMPOUNDS and specifying those COMPOUNDS, if any, which are covered by RESEARCHERS’
PATENTS. 

  

	3.2	Not later than two (2) weeks after delivery of such information by the RESEARCHERS, SENETEK will select and advise the RESEARCHERS, in writing, of those COMPOUNDS on which it
wishes to conduct TESTING at that time. Notwithstanding the foregoing, as regards COMPOUNDS which the RESEARCHERS’ listing under Article 3.1 specifies are covered by the RESEARCHERS’ PATENTS, if SENETEK does not give the RESEARCHERS
written advice that it wishes to conduct TESTING of any such COMPOUND within four (4) months after it receives the listing provided for in Article 3.1, SENETEK shall be considered to have waived its rights to such COMPOUND for all purposes of
this AGREEMENT and the RESEARCHERS shall be free to commercialize such COMPOUND themselves, or enter into an evaluation agreement or license or other agreement with respect thereto with any third party on such terms as they may determine in their
sole discretion, subject, however, to SENETEK’s rights, if any, under the SENETEK PATENTS and provided, however, that before RESEARCHERS shall enter into an evaluation agreement or license or other agreement with any third party,
RESEARCHERS shall give notice to SENETEK of the terms on which they propose to enter into such evaluation agreement or license or other agreement and SENETEK shall have thirty (30) days to enter into such agreement with the RESEARCHERS on the
same terms, providing these terms are not worse for the RESEARCHERS than the terms in Annex 1- License Agreement Term Sheet, in which case the terms of Annex 1 will be used. 

  

	3.3	The RESEARCHERS shall within two (2) weeks of receipt of each advice of SENETEK specifying selected COMPOUNDS it then wishes to TEST, deliver the selected COMPOUNDS to SENETEK
in a quantity of at least 100 mg each. 

  

	3.4	If practicable, not later than nine (9) months after each delivery by the RESEARCHERS of the listing of COMPOUNDS as provided in Article 3.1, SENETEK will provide the
RESEARCHERS with a report of the results of the TESTING of the new COMPOUNDS set forth in such listing. SENETEK will also indicate those COMPOUNDS for which SENETEK wishes to be granted a license. SENETEK may, if it so chooses, deliver such reports
and indicate COMPOUNDS it wishes to license on more than one occasion during such period. Such license shall be exclusive and worldwide, for all applications. 

  

 Phloretamide 
 4 

	3.5	Within three (3) months of SENETEK’s decision to license COMPOUNDS as provided in Article 3.4, the PARTIES will enter into a License Agreement with respect to such
COMPOUNDS having principal terms as set forth in Annex 1- License Agreement Term. The final details of the License Agreement will be negotiated in good faith by the PARTIES hereto. 

  

	3.6	If SENETEK does not deliver one or more reports as provided in Article 3.4 or, having delivered such report or reports, decides not to execute a License Agreement negotiated by the
PARTIES as provided in Article 3.5, as to any particular COMPOUND or COMPOUNDS covered by any NEW PATENT APPLICATION, then the PARTIES will agree how to commercialize such COMPOUNDS and how to share revenues from such commercialization. Any such
agreement on particular COMPOUNDS will be recorded in writing, signed by all PARTIES, and will become an appendix to this AGREEMENT. In case of COMPOUNDS covered by RESEARCHERS’ PATENTS, RESEARCHERS shall be free to commercialize such COMPOUND
or COMPOUNDS themselves or enter into an evaluation agreement or license or other agreement with respect thereto with any third party on such terms as they may determine in their sole discretion, subject, however, to SENETEK’s rights, if
any, under the SENETEK PATENTS. 

  

	3.7	RESEARCHERS agree that they will not enter into any cooperative research and development agreement with any third party involving any chemical compounds other than COMPOUNDS for
cosmeceutical or anti-aging dermatological uses without first offering to SENETEK the opportunity to enter into such cooperative research and development agreement instead of such third party on the same terms as those proposed by or to such third
party. SENETEK will exercise its right of first refusal within 4 weeks of receiving the proposed cooperative research and development agreement. 

  

	3.8	RESEARCHERS represent and warrant to SENETEK that their entering into and performing this AGREEMENT will not violate any agreement or obligation of either of the RESEARCHERS with or
to any third party or give rise to any claim by any third party. The RESEARCHERS shall deliver to SENETEK, together with the AGREEMENT signed on their behalf, letters signed by authorized representatives of Ministry of Science and Information (MNII)
and any other legal entity with which any of RESEARCHERS are affiliated, waiving any claim against SENETEK related to the subject matter of this AGREEMENT. 

 ARTICLE 4 - ADDITIONAL CONSIDERATION; DEVELOPMENT OF SELECTED COMPOUNDS 
 In addition to the RESEARCHERS’ rights
of patent ownership under Article 5, as additional consideration for the rights granted to SENETEK herein SENETEK agrees that if SENETEK advises the RESEARCHERS as provided in Article 3.2 that it wishes RESEARCHERS to conduct TESTING on any COMPOUND
or COMPOUNDS, SENETEK will be obligated to payor reimburse the RESEARCHERS for the expenses of such TESTING and/or further evaluation, in vitro testing, and development of the selected COMPOUNDS (collectively with 

  

 Phloretamide 
 5 

 
the TESTING, the ‘R&D”). Such payments to the RESEARCHERS shall be made by bank transfer monthly, as such expenses are incurred, to the account
titled: 
 BANK NAME:. 
 ADDRESS: 
 BRANCH NO: 
 SWIFT NO: 
 ACCOUNT NO: 
 NAME OF ACCOUNT HOLDER: 
 IBAN: 
 If the PARTIES agree that any R&D can most efficiently and
effectively be done by the RESEARCHERS or by a third party laboratory with which the RESEARCHERS have a relationship, such expenses shall be billed at the RESEARCHERS’ direct cost of conducting or contracting out such activities. If the PARTIES
agree that any R&D can most efficiently and effectively be done by SENETEK’s dedicated laboratories or by a third party laboratory or academic institution with which SENETEK has a relationship, SENETEK shall pay for such activities and
provide the RESEARCHERS with documentation of such payment. 
 It is agreed by the PARTIES that they shall consult in good faith regarding the nature, scope
and costs of all R&D, the protocols therefor and the most efficient and effective sourcing thereof, provided that if agreement cannot be reached between the PARTIES within a reasonable time (having in mind the time limits set forth
herein), SENETEK’s position shall prevail. SENETEK shall own all rights to any and all test reports and test results from R&D paid for or reimbursed by SENETEK as above provided, and the RESEARCHERS agree not to make any publication or
other disclosure thereof without SENETEK’S prior written approval. 
 ARTICLE 5 - INTELLECTUAL PROPERTY AND EXPLOITATION OF THE RESULTS

  

	5.1	INVENTIONS THAT MAY BE CREATED UNDER RESEARCH CO-OPERATION OF PARTIES 

 In the event and on each occasion that the TESTING of the COMPOUNDS reveals an effect of any of the COMPOUNDS that is not covered by the SENETEK PATENTS or the RESEARCHERS’ PATENTS and that merits patent
protection, the following arrangement shall apply: 
 (a) the PARTIES shall collaborate in the preparation of documents required for the
filing of a patent application on each such invention; 
 (b) all such patent applications shall be filed and owned by the RESEARCHERS, and
SENETEK shall have the right to an exclusive licence for use world-wide, for all applications; 
 (c) each patent application shall include
the names of those employees of the PARTIES (as co-inventors) that were responsible for the development of the invention; 
 (d) the PARTIES
will agree on the filing of foreign patent protection; 
 (e) in case SENETEK executes its right to license a COMPOUND covered by a patent
prepared under this Article 5.1, SENETEK will take over the cost of obtaining and maintaining the patent protection of the invention; provided that if such patent covers COMPOUNDS which SENETEK has elected not to license or claims
fields of use for COMPOUNDS licensed to SENETEK that are beyond the fields of use SENETEK has 

  

 Phloretamide 
 6 

 
elected to license, the PARTIES shall share such cost according to the commercial potential of SENETEK’S COMPOUND and/or field of use and such
COMPOUND(S) and/or fields of use not licensed to SENETEK. 
 (f) the license fee paid by SENETEK for the grant to it of an exclusive license
shall take into account the contribution made by SENETEK (both of cash and intellectual property) to the jointly developed invention; 
 (g)
if the RESEARCHERS do not wish to file a patent application covering a jointly developed invention in a certain TERRITORY, SENETEK may file a patent application covering the jointly developed invention in such TERRITORY at its own cost in which case
the patent protection obtained shall be owned one hundred percent (100%) by SENETEK. 
  

	5.2	All scientific data regarding patent applications will be written by the RESEARCHERS, in English, and will be presented to SENETEK for review and comments. Each patent application
will be first filed in the country of origin as a provisional patent application, and within one year it will be filed as PCT in all other territories to be covered. 

 ARTICLE 6 - CONFIDENTIALITY 
  

	6.1	In consideration of the use of the COMPOUNDS by SENETEK and receipt by the RESEARCHERS of periodic reports on results of TESTING, and in consideration of joint research performed by
PARTIES, each receiving PARTY agrees that during the term of this AGREEMENT, it will not, except to the extent authorized by disclosing PARTY in writing, use for any purpose other than those described herein, or publish, disclose or release to any
third party, any information regarding the R&D or TESTING conducted on such COMPOUND, except as may be required in connection with the filing and prosecution of NEW PATENT APPLICATIONS. Each RESEARCHER, by signing this AGREEMENT, agrees to be
bound by all of the terms of this Article 6 with the same effect as if such RESEARCHER were the RESEARCHERS. 

  

	6.2	The above restraints on use, release, and/or disclosure shall not apply to information or effects and applications of COMPOUNDS which: 

  

	 	•	 	 at the time of delivery or disclosure are known to the receiving PARTY; 

  

	 	•	 	 at the time of delivery or disclosure or subsequent thereto are generally available to the public through no fault of the receiving PARTY;

  

	 	•	 	 subsequent to the time of delivery or disclosure are independently developed by an employee or agent of the receiving PARTY who does so without reference to or
knowledge of the disclosing PARTY’S information or the COMPOUNDS; 

  

	 	•	 	 subsequent to the time of delivery or disclosure become or are made available to the receiving PARTY by a third party having the lawful right to do so; or

  

	 	•	 	 subsequent to the time of such delivery or disclosure become subject of another agreement between the PARTIES hereto which permits use, release and/or disclosure.

 The PARTY seeking to assert any of the above exceptions shall have the burden of proof. 
  

	6.3	The PARTIES shall maintain the obligation of confidentiality for five years after the expiration of this AGREEMENT. 

  

 Phloretamide 
 7 

 ARTICLE 7 - FORCE MAJEURE 
  

	7.1	Neither PARTY shall be liable for failure in performance hereunder if occasioned by any cause beyond the control of the P ARTY, such as for example fire, flood, strikes, inevitable
accidents, war, embargo, blockade, legal restrictions, governmental relations, etc. 

  

	7.2	The occurrence of the Force Majeure shall be notified to the other PARTY in writing within 10 working days and shall be verified by the respective chamber of commerce within further
10 working days at the latest. Each PARTY undertakes to do its utmost in order to re-establish conditions favorable for the performance of this AGREEMENT and shall inform the other PARTY about steps it has taken. The term of this AGREEMENT will be
extended by the period the Force Majeure had lasted. 

 ARTICLE 8 - TERM OF THE AGREEMENT 
  

	8.1	This AGREEMENT shall be become effective on the EFFECTIVE DATE and shall continue and remain in effect according to its terms without limitation of time until the expiration of the
last VALID CLAIM of any NEW PATENT APPLICATION, unless terminated in accordance with Article 8.2 or 8.3. 

  

	8.2	This AGREEMENT can be prematurely terminated by agreement of both PARTIES or may be prematurely terminated by a PARTY upon not less than six months’ prior written notice to the
other PARTY. 

  

	8.3	A PARTY shall have the right to terminate this AGREEMENT forthwith at any time by notice in writing to the other PARTY if the other PARTY commits a material breach of any of the
terms of this AGREEMENT and does not within 30 days of receipt of notice of the breach (if the same be capable of remedy) remedy such breach. 

  

	8.4	Termination of this AGREEMENT for any reason shall not bring to an end the confidentiality obligations of the PARTIES hereto; and/or the rights and obligations (if any) on each
PARTY hereunder. 

 ARTICLE 9 - DISPUTES 
  

	9.1	In the event of any difference or dispute arising between the PARTIES hereto concerning the construction or performance of this AGREEMENT or its validity, the PARTIES shall first
consult together in good faith and attempt to settle the matter amicably. 

  

	9.2	Any disputes relating to the interpretation, construction, performance or validity of this AGREEMENT which cannot be resolved under Article 10.1 above, shall be referred to a final
decision of a panel of three (3) arbitrators (the “Panel”), appointed under and acting in accordance with the Rules of the Arbitration Court of the International Chamber of Commerce in Paris. The seat of the Arbitration Court shall be
in Vienna. 

  

 Phloretamide 
 8 

	9.3	The PARTIES specifically agree that if they are unable in good faith to reach agreement as to any details of the license agreement or agreements referred to in Article 3.5, they
shall submit such disagreement to the Panel and request that the Panel determine such disagreement in a manner consistent with ordinary course business practices as applied by reasonable business persons in the industry to which this AGREEMENT
relates. Such determination by the Panel shall be treated as a decision of the Panel for all purposes of this Article 10. 

  

	9.4	Both PARTIES agree that the decision of the Panel shall be final and binding and that they shall undertake to abide by and execute the award rendered by the arbitrators without
delay. The enforcement of such an award may be applied for at any court of competent jurisdiction. 

  

	9.5	The AGREEMENT as well as the mutual obligations arising under it shall be exclusively governed by the provisions of the substantive law of Austria. 

 ARTICLE 10 - GENERAL 
  

	10.1	This AGREEMENT constitutes the sole and entire understanding either oral or written on the subject matter of the AGREEMENT. No further agreement or understanding shall be binding
upon either PARTY hereto unless in writing signed by both PARTIES. This AGREEMENT shall not be assignable by any of the PARTIES hereto, without prior written consent of the other PARTIES. 

  

	10.2	The payments properly due to the RESEARCHERS under the AGREEMENT shall in no event be refundable to SENETEK. In the event of termination or expiration of this AGREEMENT SENETEK will
pay all and any sums due to RESEARCHERS up to the date of expiration or termination. In the event that SENETEK shall be required to pay a tax on any payment to the RESEARCHERS, it shall deduct the amount of said tax from the payment due to the
RESEARCHERS and shall provide the RESEARCHERS with a copy of the Certificate of the tax having been paid pursuant to an Agreement on Avoidance of Double Taxation or for other reasons. 

  

	10.3	The time periods provided for herein during which a PARTY is permitted or required to take any action shall be tolled and extended for such period of time, if any, as the other
PARTY is in breach of any term of this AGREEMENT. 

  

	10.4	SENETEK hereby confirms that it has the expertise necessary to make use of any licensed patents and to develop, make, have made, sell, use, and otherwise commercially exploit the
PRODUCTS. 

  

 Phloretamide 
 9 

 IN WITNESS WHEREOF, the PARTIES hereto have caused this AGREEMENT to be executed by their duly authorized
representatives in a manner legally binding upon them as of the EFFECTIVE DATE. 
  

 Phloretamide 
 10 

 ANNEX 1 
 LICENSE AGREEMENT TERM SHEET 
  

			
	Term of License:	  	The term of the Valid Claims of the licensed patent(s).
		
	Licensed Territory:	  	World-wide.
		
	Scope of License:	  	Exclusive, for all applications.
		
	Consideration:	  	Royalty of XXX of Senetek’s or its Affiliates’ Net Sales of licensed Products other than products covered by SENETEK PATENTS, and XXX of Senetek’s or its Affiliates’ Net
Sales of licensed Products covered by SENETEK PATENTS,
		
		  	Royalty of XXX of Senetek’s SUB-LICENSEES’ Net Sales of sub-licensed products other than products covered by SENETEK PATENTS, and XXX of Senetek’s SUBLICENSEES’ Net Sales of
sub-licensed products covered by SENETEK PATENTS
		
	Sub-licensing/ Assignment:	  	No limitation
		
	Senetek Covenants:	  	Validity and enforceability of License Compliance with law in performing License
		
	RESEARCHERS’ Covenants:	  	Validity and enforceability of License Maintenance and defense of licensed patents
		
	Indemnification:	  	By Senetek for liability from any non-compliance with law in manufacture, marketing or sale of licensed products.
		
		  	By the RESEARCHERS for invalidity or unenforceability of licensed patents up to the value of payments received from SENETEK in preceding calendar year.
		
	Termination:	  	By either Party for material breach by the other Party or insolvency or liquidation of the other Party.
		
	Confidentiality:	  	Per basic AGREEMENT Agreed press release upon signing
		
	Applicable Law:	  	Per basic AGREEMENT.
		
	Other Terms:	  	See Annex 2

  

 Phloretamide 
 11 

 ANNEX 2 
 COMMERCIAL TERMS GOVERNING LICENSE 
 1. SENETEK will inform RESEARCHERS in writing of the dates of each FIRST
COMMERCIAL SALE, within 2 (two) months of occurrence of such FIRST COMMERCIAL SALE. 
 2. Where PRODUCT is sold in a currency other then US Dollars, the rate
of exchange to be used for converting such currency into US Dollars shall be the exchange rate, as published in the Financial Times, at the end of the relevant accounting period. 
 3. The payments shall be made within 60 days of the end of calendar quarter, and shall be accompanied by a statement which shall show on a country by country basis for the previous quarter all monies due to the
RESEARCHERS. Said sales report shall include the sales figures used to calculate the royalties due to the RESEARCHERS, as well as the quantities sold, the unit price of any quantity of the PRODUCTS both by SENETEK and its AFFILIATES or
SUB-LICENSEES. 
 4. The royalty properly due to the RESEARCHERS shall in no event be refundable to SENETEK. 
 5. In the event that SENETEK shall be required to pay a tax on any payment to the RESEARCHERS, it shall deduct the amount of said tax from the payment due to the
RESEARCHERS and shall provide the RESEARCHERS with a copy of the Certificate of the tax having been paid pursuant to an Agreement on Avoidance of Double Taxation or for other reasons. 
 6. SENETEK shall prepare accounts, which shall include all the elements necessary to precisely calculate the NET SALES and NET ROYALTY within the framework of the AGREEMENT. If necessary these accounts shall be made
available once a year with 30 days notice to the RESEARCHERS or an accredited designee of the RESEARCHERS during the term of the AGREEMENT and for one year thereafter. These accounts shall be prepared annually within 90 (ninety) days of the closing
date of December 31 of each year which represents the end of SENETEK’s fiscal year. 
 7. Any sums which remain unpaid within the periods set out
hereunder shall be subject to interest of 3% (three percent) over above LIBOR as published in the Financial Times at the end of the relevant accounting period, without prejudice to the RESEARCHERS’ right to terminate the contract in accordance
with Article 10 of the present AGREEMENT. 
 8. The RESEARCHERS shall have the right once a year with 30 days notice to audit or have audited the sales
accounts kept by SENETEK. Should there be an audit, an expert accountant shall be appointed by mutual agreement of both PARTIES at the expense of the RESEARCHERS, except that if the amount of installments shown by such audit to be due to the
RESEARCHERS exceed the amount actually paid by SENETEK by 5% (five percent), then such expenses shall be paid by SENETEK and any back payments shall be reimbursed with per the Agreement. 
 9. SENETEK agrees to make reasonable efforts to make, have made, sell and otherwise commercially exploit the PRODUCTS, using similar efforts devoted to products of similar nature and similar markets. 
  

 Phloretamide 

 10. SENETEK agrees to provide annual reports on the development and exploitation of the PRODUCTS. 
 11. SENETEK and its AFFILIATES agree not to use the names of the RESEARCHERS, any trademark, distinctive sign or adaptations thereof which belongs to the RESEARCHERS or
the names of RESEARCHERS inventors or of any RESEARCHERS agent, on packaging, labeling, advertising or promotional materials for the PRODUCTS without receiving prior written approval from the RESEARCHERS and the natural person concerned, as the case
may be. 
 12. PRODUCTS shall be commercialized by SENETEK, its AFFILIATES and its SUBLICENSEES under their own trademarks. The RESEARCHERS shall have no
rights to such trademarks. All administrative authorizations obtained by SENETEK, its AFFILIATES or its LICENSEES for the purpose of manufacturing and/or commercializing the PRODUCTS shall be obtained for them. The RESEARCHERS shall claim no rights
thereto. 
 13. SENETEK accepts the obligation to inform by writing the RESEARCHERS of all administrative marketing approvals that it obtains for the purpose
of manufacturing and/or commercializing the PRODUCTS no later than 3 (three) months after obtaining such final authorizations. 
  

 Phloretamide 
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]